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Abstract During the past few years many chimeric proteins
have been developed to target and kill cells expressing specific
surface molecules. Generally, these molecules carry a bacterial
or plant toxin that destroys the unwanted cells. The major
obstacle in the clinical application of such chimeras is their
immunogenicity and non-specific toxicity. We have developed a
new generation of chimeric proteins, taking advantage of
apoptosis-inducing proteins, such as the human Bax protein, as
novel killing components. The first prototype chimeric protein,
IL2-Bax, directed toward IL2R-expressing cells, was con-
structed, expressed in Escherichia coli and partially purified.
IL2-Bax increased the population of apoptotic cells in a variety
of target T cell lines, as well as in human fresh PHA-activated
lymphocytes, in a dose-dependent manner and had no effect on
cells lacking IL2R expression. The IL2-Bax chimera represents
an innovative approach for constructing chimeric proteins
comprising a molecule that binds a specific cell type and an
apoptosis-inducing protein. Such new chimeric proteins could be
used for targeted treatment of human diseases.
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1. Introduction
The advent of the monoclonal antibody and recombinant
DNA technologies has led to the discovery of numerous cell
surface molecules associated with speci¢c cell populations.
Based on the di¡erential expression patterns of these mole-
cules, immunotoxins have been constructed to speci¢cally tar-
get and destroy cells expressing such surface molecules,
among them cancer cells and cells involved in disorders of
the immune system. The targeting moiety of the immunotox-
ins consists of whole antibodies or antigen-binding domains,
including the Fv portion of an antibody (single-chain immu-
notoxins) or growth factors and cytokines (chimeric proteins).
These molecules are generally fused to various mutant forms
of bacterial or plant toxin molecules to destroy the unwanted
cells [1]. The major drawback in the clinical application of
these molecules is the human immune response they elicit,
mainly toward the toxin moiety. Bacterial toxins like Pseudo-
monas exotoxin A (PE) and diphtheria toxin are highly im-
munogenic and cannot be humanized by standard techniques.
In addition, each immunotoxin displays some degree of
non-speci¢c toxicity, and, at su⁄ciently high concentrations,
damages normal cells that do not express the speci¢c target
antigen. This non-speci¢c toxicity of immunotoxins/chimeric
proteins is the dose-limiting factor in immunotoxin therapy.
Thus, it has become clear that new approaches are needed to
produce novel targeting molecules, mainly composed of hu-
man, non-immunogenic toxins.
We have developed a new generation of chimeric proteins,
exploiting apoptosis-inducing proteins, such as the human
Bax protein, as novel killing components instead of the trou-
blesome bacterial or plant toxins. Bax is a pro-apoptotic
member of the Bcl-2 protein family. Bax hetrodimerizes with
Bcl-2 in vivo [2] but is also able to regulate apoptosis inde-
pendently [3,4]. Induction of Bax expression is su⁄cient to
induce apoptosis and does not require any additional death
stimulus [5]. Bax forms channels in lipid membranes [6,7] and
directly induces the release of cytochrome c from isolated
mitochondria [8]. Recently, both Bax frame-shift mutations
and loss-of-function mutations [9,10] were detected in hema-
topoietic malignancies and were found to be associated with
resistance to apoptosis [9].
Moreover, elevations in Bax protein levels are induced in
several clinically relevant settings where cell death occurs, in-
cluding tumor cells during responses to chemotherapy and
radiation [11,12], neurons following cerebral ischemia [13]
and myocardiocytes following acute myocardial infarction
[14].
To validate the use of pro-apoptotic proteins as the killing
moiety in chimeric proteins, we chose a well known target, the
interleukin 2 receptor (IL2R). IL-2-toxin chimeric proteins,
such as IL2-Pseudomonas exotoxin (IL2-PE), successfully
eliminate activated T cells, both in vitro and in vivo [15].
Another chimeric protein, DAB386-IL2, is now in clinical
trials in CTCL patients [16,17]. In addition, the K chain of
the IL2R was successfully targeted by the murine or the
humanized anti-Tac antibody in cancer patients as well as in
patients after transplantation [18,19].
In the present work we prove that the novel chimera, IL2-
Bax, speci¢cally targets IL2R-expressing cells and induces
cell-speci¢c apoptosis.
2. Materials and methods
2.1. Construction of a plasmid encoding the IL2-Bax protein;
expression of the protein and partial puri¢cation
pHL906 [20], which carries the fusion gene IL2-PE40, was cut with
HindIII and PpuMI, removing the PE sequence, and the vector frag-
ment was eluted.
The cDNA for human BaxK was obtained by RT-PCR, using RNA
isolated from fresh human lymphocytes. Total RNA was isolated and
was then reverse transcribed into ¢rst strand cDNA, using the reverse
transcription system (Promega, USA) according to the manufacturer’s
instructions. The cDNA was diluted to a total volume of 1 ml with
10 mM Tris-HCl, pH 7.6, 1 mM EDTA and stored at 4‡C until use.
The Bax fragment was generated by PCR, using the above cDNA and
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a pair of synthetic oligonucleotide primers: 5P-CGGAATTCAA-
GCTTTGGACGGGTCCGGGGGA-3P (sense) and 5P-CGGAATT-
CAGGTCCTTCAGCCCATCTTCTTC-3P (antisense) covering the
entire coding region. The reaction mixture was incubated in a DNA
thermal cycler (MJ Research Inc., Watertown, MA, USA) for
33 cycles. Each cycle consisted of 1 min at 95‡C, 1 min at 65‡C and
2 min at 72‡C. The Bax fragment, after digestion with PpuMI and
HindIII enzymes, was ligated to the vector fragment. The resulting
plasmid pAY1 carries the Bax human sequence 3P to the IL2 se-
quence. The construct was con¢rmed by restriction endonuclease di-
gestion and DNA sequence analysis.
The chimeric proteins were expressed in Escherichia coli strain
BL21(VDE3). A pellet of expressing cells was suspended in 20 mM
Tris-HCl pH 8.0, 1 mM EDTA containing 0.2 mg/ml lysozyme, soni-
cated (three 30-s bursts) and centrifuged at 35 000Ug for 30 min. The
supernatant (soluble fraction) was removed and kept for analysis. The
pellet was denatured in extraction bu¡er A (6 M guanidine-HCl, 0.1 M
Tris-HCl, pH 8.6, 1 mM EDTA, 0.05 M NaCl, and 10 mM DTT) and
stirred for 1 h at 4‡C. The suspension was cleared by centrifugation at
35 000Ug for 15 min and the pellet discarded. The protein solution
was diluted 1:100 in refolding bu¡er (20 mM Tris-HCl, pH 8.0, 1 mM
EDTA, 0.25 M NaCl and 5 mM dithiothreitol) and kept at 4‡C for
48 h.
Two microgram (total protein) of the various fractions was run on
a 12% SDS-PAGE gel.
2.2. Western blot analysis of cell fractions expressing IL2-Bax
Samples of the various protein fractions were Western blotted and
analyzed with anti-Bax (Pharmingen, San Diego, CA, USA, 1:2500)
and anti-IL2 (Endogen, Boston, MA, USA, 1:5000), using the ECL
kit for detection.
2.3. FACS analysis
Cells (0.5U106/10 ml) were centrifuged at 450Ug for 6 min, washed
with cold PBS and resuspended in 300 Wl of PBS. The cells were ¢xed
with 5 ml methanol and left at 320‡C for at least 1 h. The cells were
then centrifuged at 800Ug for 5 min, resuspended in 100 Wl PBS and
diluted to a ¢nal volume of 1 ml with PBS. Cells were incubated on
ice for an additional 30 min, centrifuged at 800Ug for 5 min and
resuspended in 0.5 ml PBS. 10 Wl RNase (50 Wg/ml) and propidium
iodide (PI, 5 Wg/ml) were added to the cell samples which were then
FACS analyzed for DNA content as a function of cell number.
All centrifugations were carried out at 4‡C. All solutions used were
chilled to 4‡C before use.
For competition assays, 10 Wg/ml rIL2 or anti-Tac (Genzyme, Cam-
bridge, MA, USA) and IL2-Bax was added at a ¢nal concentration of
5 Wg/ml for 16^18 h. Samples were analyzed with a FACScan (Becton
Dickinson, Immunocytometry Systems, San Jose, CA, USA) using the
LYSYS II program.
2.4. Preparation of fresh activated human lymphocytes
Human peripheral blood lymphocytes from healthy donors were
isolated on a Ficoll-Isopaque gradient (1.077) and used immediately.
Lymphocytes were cultured in 5% CO2 in air in RPMI 1640 medium
supplemented with 10% fetal calf serum, 200 mg/ml L-glutamate,
50 mg/ml penicillin, 50 mg/ml streptomycin, 50 mg/ml glutamine,
5U1035 M L-mercaptoethanol and PHA (5 Wg/ml) for 3 days. The
activated cells were washed and resuspended in the presence of
10 U/ml rIL2 to maintain cell viability. Increasing concentrations of
IL2-Bax were then added to the activated lymphocytes for 24 or
48 h and the cells were then stained with PI (5 Wg/ml) and FACS
analyzed.
2.5. TUNEL assay
We used the apoptosis detection system, £uorescein (Promega,
USA) and the slides were screened with a Zeiss Axoplan microscope
to visualize the £uorescein-12-dUTP labeled DNA. A color ¢lter (¢l-
ter set 23, with dual excitation at 485 and 546 nm) was used. Photo-
graphs were taken with ASA/400 color ¢lm (exposure time 15^60 s).
Cells (0.5U106/10 ml) were incubated overnight with 5 Wg/ml of
IL2-Bax.
2.6. Detection of DNA fragmentation
DNA was extracted from 2B4 cells exposed to dexamethasone
(5U1036 M) or IL2-Bax (5 Wg/ml) for 24 or 48 h as described in
[21] and run on 1.5% agarose for detection of DNA ladders.
3. Results
3.1. Construction and expression of the plasmid encoding
IL2-Bax
We constructed a plasmid (pAY1) for the expression of the
chimeric protein, under the control of a T7 promoter (Fig.
1A). The plasmid was transformed into E. coli strain BL-21
(VDE3) and the chimeric protein, termed IL2-Bax, was ex-
pressed. IL2-Bax, mainly found in the insoluble fraction of
the expressing cells (Fig. 1B), reacted with both anti-Bax
and anti-IL2 when tested by Western blot analysis (Fig.
1C), con¢rming the cloning and production of the in-frame
full-length chimeric protein. The insoluble fraction of express-
ing cells was denatured and refolded, and this partially en-
riched protein preparation was used in the following experi-
ments.
3.2. E¡ect of IL2-Bax on target cells
We evaluated the e¡ect of IL2-Bax on HUT102 cells [22],
human activated T cells expressing IL2R, by closely monitor-
ing the viability of the cultured cells exposed to the new chi-
mera. IL2-Bax e⁄ciently inhibited cell growth and eventually
led to cell death (Fig. 2A,B).
As a more direct test of IL2-Bax function, we measured the
induction of apoptosis in the target cells by FACS analysis.
IL2-Bax caused an increase in the population of apoptotic
cells in HUT102 cells in a dose-dependent manner, as assessed
by cell cycle staging of the cells with PI (Fig. 3). The highest
response was observed at 5 Wg/ml ( = 1.4U1037 M of IL2-Bax)
of the chimeric protein.
IL2-Bax also induced apoptosis in various other IL2R-pos-
itive T and B cell lines (Table 1) that express various levels
and species of the IL2R chains [23,24]. The chimeric protein
induced apoptosis in the murine 2B4 T cell line as well.
IL2-Bax induced apoptosis not only in established cell lines
but also in fresh human PHA-activated lymphocytes obtained
from control donors (Fig. 4). This e¡ect could be blocked by
anti-Tac (Fig. 4).
3.3. Speci¢city of IL2-Bax response
IL2-Bax displayed speci¢c activity, as it was inhibited by
recombinant IL2 (Fig. 3) or anti-Tac, a monoclonal antibody
against the IL2R-K chain, that blocks the binding of IL2 to its
high a⁄nity receptor (Fig. 3).
As a control we used the chimeric protein IL2-PE, which
targets the same cells but carries the classical bacterial toxin
PE as the killing moiety. IL2-PE did not cause any measura-
ble apoptotic e¡ect in the target cells, although it caused in-
hibition of protein synthesis within the cells (results not
shown).
Table 1
Percent of apoptotic cells in IL2R-positive cell lines exposed to IL2-
Bax
Cell line IL2-Bax (5 Wg/ml) % apoptotic cellsa
HUT102 43.2
MT-1 29.8
ARH-77 25.8
2B4 18.3
aResults are expressed as the mean of 3^4 experiments performed
for each cell line. Experiments were repeated with variations of no
more than þ 3%.
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IL2-Bax did not have any e¡ect on cells lacking IL2R ex-
pression, such as CEM (a human T cell line), Km3 (a human
non-T, non-B stem cell line), Nalm 6 (a human pre-B cell
line), or on cell lines of non-hematopoietic origin such as
Colo205 (a human colon adenocarcinoma cell line) and
293 cells (a human renal adenocarcinoma cell line) (Table 2).
We tested also other control chimeric proteins composed of
various irrelevant targeting moieties. None of the control pro-
teins induced apoptosis in HUT102 target cells (results not
shown).
3.4. Detection of apoptosis caused by IL2-Bax
Induction of apoptosis by IL2-Bax was also con¢rmed us-
ing the annexin-V assay on HUT102 cells for early detection
of apoptosis. The apoptotic e¡ect was already evident at 6 h
post exposure to IL2-Bax, and peaked at 24 h (results not
shown).
As further con¢rmation of apoptosis we obtained TUNEL-
positive HUT102 cells after 24 h exposure to IL2-Bax (Fig.
5A). Similar results were observed with 2B4 cells (results not
shown). Nuclear changes, i.e. DNA fragmentation, induced
by IL2-Bax can be seen at a later stage (48 h) in the 2B4 cells
(Fig. 5B). Dexamethasone, a known inducer of apoptosis in
various cells, was used in all experiments as a positive con-
trol.
Fig. 1. A: Construction of the plasmid pAY1 that encodes the IL2-
Bax. The numbers represent the corresponding amino acids. B:
SDS-PAGE analysis of cell fractions containing the IL2-Bax chimer-
ic protein. 2 Wg (total protein) of the various fractions was run on a
12% SDS-PAGE gel. Lane 1: marker; lane 2: whole cell extract of
cells expressing IL2-Bax; lane 3: soluble fraction of the expressing
cells ; lane 4: insoluble fraction of the expressing cells. Arrow indi-
cates the IL2-Bax protein. C: Western blot analysis of cell fractions
containing IL2-Bax. Lanes 1 and 4: whole cell extract of cells ex-
pressing IL2-Bax; lanes 2 and 5: soluble fraction of the expressing
cells ; lanes 3 and 6: insoluble fraction of the expressing cells. Lanes
1^3, using anti-IL2 antibodies. Lanes 4^6, using anti-Bax antibodies.
Arrow indicates the IL2-Bax protein. For experimental details see
Section 2.
Fig. 2. E¡ect of IL2-Bax on HUT102 cell growth. A: Total number
of cells in cultures in the presence (^b^) or absence (^E^) of IL2-
Bax (2.5 Wg/ml). B: Number of living cells in culture exposed to
IL2-Bax (2.5 Wg/ml). Cells were stained with trypan blue (0.4%).
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4. Discussion
The development of speci¢c targeted agents remains a ma-
jor goal in the treatment of human diseases. The hallmark of
an e¡ective therapeutic modality is its speci¢city, the ability to
interact with the target organ and its lack of undesirable ef-
fects in the human recipient.
We report here our novel approach for developing chimeric
proteins that can be used for targeted therapy in human dis-
eases. The ¢rst prototype molecule, IL2-Bax, speci¢cally tar-
gets IL2R-expressing cells and induces cell-speci¢c apoptosis.
IL2-Bax induced apoptosis in the target cells in a dose-
dependent manner (Fig. 3). The strongest response to IL2-
Bax was observed at 1.4U1037 M (Fig. 3) of the chimeric
protein. These concentrations of Bax are within the physio-
logical range as it has been previously reported that basal
concentrations of Bax protein in a variety of human tumor
cell lines can be as high as V0.1U1036 M [8], and Bax
protein levels can rise in some tumor cells by over 10-fold
following exposure to chemotherapeutic drugs or Q-radiation
[11].
The novel chimeric protein, carrying the human Bax pro-
tein, induced apoptosis also in the mouse 2B4 T cell line, in
accordance with a recent report demonstrating that a speci¢c
domain of Bax (aa 112^192) was responsible for mammalian
apoptosis in a murine promyeloid cell line, FDC-P1, as well as
for bacterial death [25].
Our results show that targeting of the Bax protein via the
IL2R in the form of a chimeric protein is su⁄cient to induce
apoptosis in the target cells in the absence of any additional
death stimulus. To elucidate the mechanism by which IL2-Bax
induces apoptosis, we used confocal microscopy to follow the
path of IL2-Bax within the treated cells. Preliminary results
revealed that following 24 h exposure to IL2-Bax, when apop-
tosis is already evident, the chimera colocalizes with the mi-
tochondria, suggesting that IL2-Bax may play a similar role to
the natural endogenous Bax protein (R. Aqeilan and H. Lor-
berboum-Galski, manuscript in preparation).
Although proteins such as Bax are intracellular proteins,
they are of human origin and, as such, they are expected to
display reduced immunogenicity in human recipients. Further-
more, killing target cells via the apoptotic pathway, we min-
imize any tissue damage or systemic response. The apoptotic
cells shrink and condense, while the organelles and plasma
membranes retain their integrity, then the dead cells are rap-
idly phagocytosed by neighboring cells or macrophages, dis-
appearing before there is any leakage of their content.
IL2-Bax is now being developed for treatment of graft re-
Fig. 3. Induction of apoptosis in HUT102 cells by IL2-Bax: FACS analysis. a^d: dose response; e: competition by anti-Tac; f : competition by
rIL2. Samples were FACS analyzed for DNA content (x-axis) as a function of cell number (y-axis) as described in Section 2.
Fig. 4. Induction of apoptosis in human activated fresh lymphocytes by IL2-Bax. Human peripheral blood lymphocytes from healthy donors
were separated, activated with PHA and measured for their response to IL2-Bax. Increasing concentrations of IL2-Bax were added to the acti-
vated lymphocytes for 24 and 48 h. Cells were then stained with PI (5 Wg/ml) and FACS analyzed as described in Section 2 and Fig. 3.
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Fig. 5. A: TUNEL-positive HUT102 cells after exposure to IL2-Bax. a: control cells (U200); b: cells exposed to IL2-Bax (U200); c: single
cell from b, magni¢ed U1000. Normal cells stain red, apoptotic cells stained yellow-red. B: DNA fragmentation in 2B4 cells exposed to IL2-
Bax. For detection of DNA fragmentation, DNA was extracted from 2B4 cells exposed to dexamethasone (5U1036 M) or IL2-Bax (5 Wg/ml)
for 24 or 48 h. Lane 1: DNA extracted from control 2B4 cells, not exposed to any inducer (48 h.); lane 2: DNA extracted from 2B4 cells ex-
posed to dexamethasone (5U1036 M) for 48 h; lane 3: DNA extracted from 2B4 cells exposed to IL2-Bax (3 Wg/ml) for 48 h; lane 4: DNA
extracted from 2B4 cells exposed to IL2-Bax (5 Wg/ml) for 48 h. In both assays 0.5U106/10 ml cells were incubated with IL2-Bax.
FEBS 22496 25-8-99 Cyaan Magenta Geel Zwart
R. Aqeilan et al./FEBS Letters 457 (1999) 271^276 275
jection, certain autoimmune diseases, infectious diseases and
several malignancies.
IL2-Bax represents a novel approach for constructing chi-
meric proteins by fusing a targeting molecule, that binds to a
speci¢c cell type, to a wide range of apoptosis-inducing pro-
teins. These novel chimeras are expected to selectively elimi-
nate speci¢c cell types both in vitro and in vivo.
Reagents such as IL2-Bax open up new prospects for the
speci¢c targeted therapy of human diseases.
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Table 2
E¡ect of IL2-Bax on IL2R-negative cell lines
Cell line Cell type Percent of apoptotic cellsa
Control IL2-Bax (5 Wg/ml)
CEM T cell (IL2R3) 1.2 2.2
Km3 non-B, non-T stem cells 2.6 4.3
Nalm 6 pre-B cells 4.2 5.8
Colo205 colon-adenocarcinoma 7.2 9.8
293 renal adenocarcinoma 3.8 5.3
HUT102 T cells (IL2R+) 9.0 46.7
aResults are expressed as means of 3^4 experiments performed for
each cell line. Experiments were repeated with variations of no
more than þ 3%.
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